Bosun Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$796K Hold
3,661
0.43% 33
2025
Q4
$836K Sell
3,661
-139
-4% -$31.7K 0.4% 31
2025
Q3
$880K Sell
3,800
-117
-3% -$23.8K 0.45% 22
2025
Q2
$727K Sell
3,917
-331
-8% -$61.5K 0.22% 109
2025
Q1
$890K Buy
4,248
+20
+0.5% +$3.89K 0.38% 64
2024
Q4
$751K Sell
4,228
-202
-5% -$37.1K 0.33% 87
2024
Q3
$875K Buy
4,430
+199
+5% +$37.1K 0.42% 67
2024
Q2
$726K Buy
4,231
+403
+11% +$66.8K 0.43% 60
2024
Q1
$697K Sell
3,828
-4,683
-55% -$807K 0.4% 78
2023
Q4
$1.32M Sell
8,511
-198
-2% -$28.9K 1.31% 18
2023
Q3
$1.3M Sell
8,709
-298
-3% -$43.7K 1.41% 15
2023
Q2
$1.21M Buy
9,007
+700
+8% +$103K 1.19% 15
2023
Q1
$1.32M Buy
8,307
+3,300
+66% +$505K 1.51% 9
2022
Q4
$809K Sell
5,007
-100
-2% -$15.3K 1.15% 15
2022
Q3
$685K Buy
5,107
+1,500
+42% +$215K 1.06% 17
2022
Q2
$552K Sell
3,607
-5
-0.1% -$764 0.76% 29
2022
Q1
$585K Hold
3,612
0.61% 31
2021
Q4
$489K Buy
+3,612
New +$427K 0.44% 34

Other funds holding ABBV

Bosun Asset Management's ABBV Position: Q1 2026 in Review

Bosun Asset Management held its AbbVie (ABBV) position steady in Q1 2026 at 3,661 shares worth $796K. The position accounts for 0.43% of the portfolio, ranked #33.

Bosun Asset Management first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.32M in Q1 2023. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Bosun Asset Management held 3,661 shares of AbbVie worth $796K as of Q1 2026.
  • Bosun Asset Management left its AbbVie share count unchanged in Q1 2026.
  • AbbVie made up 0.43% of Bosun Asset Management's portfolio in Q1 2026, its #33 holding.
  • Bosun Asset Management first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • Bosun Asset Management's AbbVie position peaked at $1.32M in Q1 2023.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bosun Asset Management's 13F filing for Q1 2026, filed 11 May 2026.